期刊文献+

靶向治疗——渐行渐近 被引量:4

Molecular Targeted Therapy is Coming
下载PDF
导出
摘要 靶向药物的出现是肿瘤治疗的一个重要进展。同传统化疗相比作用机制和副反应不同,针对肿瘤特殊靶点的治疗对正常组织的毒副反应轻微。10年来,由于靶向药物的出现,给肿瘤的治疗模式带来了重大变化。单克隆抗体和小分子化合物是两种主要的靶向药物。这些药物已经逐渐由晚期一线治疗走向辅助治疗甚至新辅助治疗。虽然目前还存在很多问题,面临很多困难,但是靶向治疗代表未来的发展方向,将为改善肿瘤患者的生存发挥无法估量的作用。 The development of targeted therapy is a major breakthrough in the treatment of cancer. The mechanisms of molecular targeted therapy differed from the traditional chemotherapy. The trerapy had more effective to patients with molecular target and less'toxicity to healthy tissue in the body. Distinct mechanisms of molecular targeted therapy had Significantly changed the treatment of cancer over the past 10 years. The two main types Of targeted therapy were monoclonal antibodies and small molecule inhlbitors. Targeted drugs had been gradually used from the first-line therapy of advanced cancer to adjuvant therapy or neo-adjuvant therapy. Although there were so many problems and difficulties, the future of targeted therapy will be brilliant. And the effect to improve the survival of cancer patients will be inestimable.
出处 《医学与哲学(B)》 2012年第6期13-15,73,共4页 Medicine & Philosophy(B)
关键词 肿瘤 靶向治疗 tumor, molecular targeted therapy
  • 相关文献

参考文献18

  • 1王雅杰,王宁.肿瘤分子靶向药物分类及作用机制[J].中国实用外科杂志,2010,30(7):526-529. 被引量:17
  • 2唐平章,高丽.多学科协作时代的头颈肿瘤治疗[N].中国医学论坛报,2010-04-01(B8).
  • 3Van Cutsem E, Kohne C H, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer[J]. N Engl J Med,2009,360(14) :1408--1417.
  • 4Van Cutsem E, Kohne C H, Lang I, et al. Cetuximab plus irinotecan, fluorouracil and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival accord ing to tumor KRAS and BRAF mutatuion status[J]. J Clin Oncol, 2011,29(15) :2011--2019.
  • 5Bokemeyer C, Bondarenko I, Hartmann J T, et al. KRAS status and efficacy of firstline treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience[J]. J Clin Oncol, 2008,26:abstr 4000.
  • 6Maughan T S, Adams R A, Smith C G, et al. Addition of cetux- imab to oxaliplatin-- based first-- line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial[J]. Lancet, 2011, 377 (9783) : 2103-2114.
  • 7Perez E A, Romond E H, Suman V J, et al. Four-- year follow- up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2 positive breast cancer: joint a- nalysis of data form NCCTG N9831 and NSABP B-31[J]. J Clin Oncol,2011,29(25) :3366-3373.
  • 8Gianni L,Eiermann W, Semiglazov V, et al. Neoadjuvant chemo therapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2--positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2--negative cohort [J]. Lancet, 2010,375:377-384.
  • 9徐瑞华,王志强.大肠癌分子靶向治疗[J].中国临床肿瘤学进展,2011:261-268.
  • 10Hurwitz H, Fehrenbacher L,Novotny W, et al. Bevacizumab plus iri- notecan, fluorouracil, and leucovorin for metastatic colorectal cancer[J].N Engl J Med, 2004,350(23) ,2335--2342.

二级参考文献10

  • 1杜春燕,师英强,傅红,赵广法,周烨,蔡国响.胃肠道间质瘤103例预后分析[J].中国实用外科杂志,2007,27(4):297-299. 被引量:49
  • 2Coiffier B. Rituximab therapy in malignant lymphoma [J ]. Oncogene, 2007,26(25):3603-3613.
  • 3Jonker DJ, O'Callaghan C J, Karapetis CS, et al. Cetuximab for the treatment of eolorectal cancer [J]. N Engl J Med, 2007,357 (20):2040-2048.
  • 4Amado RG, Wolf M, Peeters M, et al. Wild-type k-ras is required for panitumumab efficacy in patients with metastatic colorectal cancer[J ]. J Clin Oncol, 2008,26(10): 1626-1634.
  • 5Untch M, Muscholl M, Tjulandin S, et al. First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the herceptin, cyclophosphamide, and epirubicin (HERCULES) trial [J]. J Clin Oncol, 2010,28(9):1473-1480.
  • 6Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer[J]. N Engl J Med, 2004,350(23):2335-2342.
  • 7Heinrich MC, Owzar K, Corless CL, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 study by Cancer and Leukemia Group B and Southwest Oncology Group [J]. J Clin Oncol, 2008,26(33):5360-5367.
  • 8Wu Y, Mok T, Chu D, et al. Evaluation of clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) recruited in China in a phase Ill, randomized, open-label, first-line study in Asia of gefitinib (G) versus carboplatin/paclitaxel (C/P)(IPASS)[J]. ASCO meeting abstracts, 2009,27(15S): 8041.
  • 9Motzer R J, Michaelson MD, Redman BG, et al. Activity of SUl1248, a muhitargeted inhibitor of vascular endothelial growth faclor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma [J]. J Clin Oncol, 2006,24(1): 16-24.
  • 10Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER-2-positive advanced breast cancer[J]. N Engl J Med, 2006,355(26):2733-2743.

共引文献16

同被引文献72

  • 1袁振刚,侯健,周帆,王东星,付卫军,陈玉宝,奚昊,杨盛玲.硼替佐米联合地塞米松治疗16例复发、难治性多发性骨髓瘤患者[J].中华血液学杂志,2006,27(10):653-655. 被引量:21
  • 2Bird J M, Owen R G, D'Sa S, et al. Guidelines for the diagnosis and management of multiple myeloma 2011 [J]. Br J Haematol, 2011,154(1) :32- 75.
  • 3Chiecchio L, Dagrada G P, Ibrahim A H, et al. Timing of acquisi- tion of deletion 13 in plasma cell dyscrasias is dependent on genetic context[J]. Haematologica, 2009,94(12) : 1708- 1713.
  • 4Mitsiades C S, Mitsiades N S, Munshi N C, et al. The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions [J]. European J Cancer, 2006,42(11):1564-1573.
  • 5Shou Y, Martelli M L, Gabrea A, et al. Diverse karyotypic abnor- malities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma[J]. Proc Natl Acad Sci U S A,2000,97(1):228-233.
  • 6Ross F M, Chiecchio L, Dagrada G, et al. The t(14;20) is a poor prognostic factor in myeloma but is associated with long term stable disease in MGUS[J]. Haematologica, 2010,95 (7) : 1221 - 1225.
  • 7Hurt E M, Wiestner A, Rosenwald A, et al. Overexpression of c maI is a frequent oncogenic event in multiple myeloma that pro- motes proliferation and pathological interactions with bone marrow stroma[J]. Cancer Ce11,2004,5(2) :191-199.
  • 8Tai Y T, Li X, Tong X, et al. Human anti-CD40 antagonist anti body triggers significant antitumor activity against human multiple myeloma[J]. Cancer Res, 2005,65 (13) : 5898- 5906.
  • 9Richardson P G, Chanan-Khan A, Schlossman R L, et al. Phase II trial of single agent bortezomib (VELCADE) in patients With previously untreated multiple myeloma [J ]. Blood, 2004, 104 ( 3 ) : 100-105.
  • 10Jagannath S, Dufie B G, Wolf J, et aL Bortezomib therapy alone and in combination with deamtasone for previously untreated symp- tomatic multiple myeloma[J]. Br J Haematol, 2005,129 (6) : 776 - 783.

引证文献4

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部